In an analysis of 1887 patients with gastro-oesophageal cancer, only those with a partial response to neoadjuvant FLOT chemotherapy showed significant improvements in disease-free survival (DFS) and overall survival (OS) when treated with adjuvant FLOT. Patients categorized as minimal responders or complete responders did not benefit from additional chemotherapy. This study suggests that assessing pathological response can optimize adjuvant treatment decisions, potentially reducing unnecessary chemotherapy exposure and its associated risks.
Multicenter Study by None None in Br J Surg
© The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
© The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.